Proactive Investors - Run By Investors For Investors

Redx Pharma unveils plans to raise up to £14.9mln to accelerate drug development plans

The proceeds will be used to develop two highly promising cancer drug treatments.
Redx Pharma unveils plans to raise up to £14.9mln to accelerate drug development plans
The cash injection will help accelerate the development effort

Redx Pharma Plc (LON:REDX) has unveiled plans to raise up to £14.9mln that will be used to develop two promising pre-clinical drug candidates.

The bulk of the money will come from a £12mln placing of stock with professional investors.

As part of that institutional round finance house Lanstead Capital is subscribing for shares worth around £4.3mln and will feed back the majority of the proceeds in monthly instalments.

Funds will also come from a smaller open offer tranche that allows existing investors to acquire equity on the same terms as the big City investors.

The shares are being sold for 37.5p each, which is a less than 10% discount to Wednesday’s closing price.

The new cash injection will allow the company to push its highly promising cancer immunotherapy drug through early clinical studies to assess its safety.

Called a Porcupine inhibitor it works by targeting cancer stems cells that can often lie dormant after traditional treatment and are associated with a recurrence of the illness.

Kill the stem cells and you have a chance of eradicating the disease completely.

Novartis currently is the only drug major with a Porcupine inhibitor in the clinic.

The funds will also be used to carry out work that will make its Bruton's tyrosine kinase inhibitor “clinic-ready”.

The Redx leukaemia treatment is being developed as a second-generation of compound with fewer side-effects than the market leader Imbruvica (often referred to as Ibrutinib).

Importantly, the company’s drug is targeted at overcoming resistance that patients have developed to the current gold standard drugs.

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
Regeneus: Access latest PPT from Proactive's CEO Sessions
June 18 2017
John Martin discussed regenerative medicine with investors.
March 28 2017
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use